Phase 3 Alzheimer's Disease Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have been clinically diagnosed with Alzheimer's disease using internationally recognised diagnostic guidelines (the IWG criteria), confirmed at the screening visit.
- People whose score on a daily living activities scale (called the ADCS-ADL) is below 73 at both the screening and baseline visits.
- People whose score on a mental ability test (called the MMSE) is between 21 and 25 at both the screening and baseline visits.
- People who have Alzheimer's-related biological markers confirmed through brain imaging (an amyloid PET scan) or through spinal fluid (CSF) testing showing abnormal levels of certain proteins (a-beta and p-tau), verified centrally before the trial begins.
- People currently taking certain Alzheimer's medications (donepezil, rivastigmine, galantamine, or memantine) who have been on a stable dose for at least 6 months before the baseline visit, with no planned changes during the trial.
- People taking cognitive health supplements (such as ginkgo biloba, omega-3, vitamin E, curcumin, or Souvenaid) who have been on a stable dose for at least 4 months before the screening visit.
- People who have a caregiver willing to attend all trial visits, who spends at least 1 hour a day with them on at least 3 days per week (or an amount the trial doctor considers sufficient), can read and speak the required language, and is mentally capable of supporting the trial requirements.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose dementia appears to be caused by something other than Alzheimer's disease, as shown by brain scan (MRI) or neurological examination.
- People with a medical condition known to cause dementia, such as an underactive thyroid, untreated vitamin B12 or folic acid deficiency, niacin deficiency, neurosyphilis, or HIV infection, identified at screening.
- People with dementia caused by substance use, Alzheimer's disease accompanied by delirium, severe delusions (scoring 4 or above on the NPI delusion scale), psychosis, current use of antipsychotic medication, or a history of significant psychiatric disorders, identified at screening.
- People who show a significant and unexplained improvement or decline in their test scores (on the ADAS-Cog and ADCS-ADL) between the screening and baseline visits, or whose scores do not match their medical history.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bruno Dubois, MD, PhD, Hôpital Universitaire Pitié-Salpêtrière, Paris, France
Phone: +33(0)147200014
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Absolute change from baseline in iADRS score at week 24
Can't join this trial?
Data last synced from ClinicalTrials.gov: 17 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.